Vanderbilt Vaccine Center

James Crowe, Jr., MD, left, and Naveenchandra Suryadevara, PhD, have discovered a monoclonal antibody with therapeutic potential that neutralizes both RSV and hMPV. (photo by Anthony Czelusniak)

Researchers discover antibody that neutralizes both RSV and hMPV

Vanderbilt and Stanford University researchers discovered a potent, cross-neutralizing human monoclonal antibody against the respiratory syncytial virus and human metapneumovirus.

VUMC, Oxford team develops ‘blueprint’ to block lethal virus

Researchers at Vanderbilt University Medical Center and the University of Oxford have determined how a human monoclonal antibody isolated at Vanderbilt in 2021 can prevent infection by the potentially lethal Sin Nombre virus.

By Bill Snyder

March 30, 2023

Crowe, Harris, Young elected as new AIMBE fellows

Vanderbilt’s James Crowe Jr., MD, Paul Harris, PhD, and Jamey Young, PhD, have been elected to the 2023 College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE).

By Mia Garchitorena-Scancarelli

March 23, 2023

Crowe’s research honored

Vanderbilt’s James Crowe Jr., MD, was among those to receive 2023 Advocacy Awards from Research!America at the biomedical research advocacy organization’s annual awards program in Washington, D.C.

By VUMC News and Communications

March 16, 2023

Scientists resurrect a ‘dead’ antibody to study protein

Vanderbilt was part of a multi-center team that resurrected a “dead antibody” to reveal the mysteries of cytochrome c, a versatile protein that is an essential part of the cell’s energy-generating capacity, and of life itself.